Sunstone Therapies

11/04/2025

Sunstone Therapies is conducting a brief survey to gain a deeper understanding of the challenges people face in seeking mental wellness to build a clearer picture of what patients need most.

Share your experience in this short, anonymous survey about finding balance and exploring new paths to well-being.
https://chat.goodchats.co/gc/emotional-wellbeing-study?utm_source=goodchat&utm_medium=affiliate&utm_campaign=sunstoneST02_partner

10/24/2025

Sunstone’s latest newsletter is set to publish shortly! If you’re not already on our mailing list, sign up to receive the latest news, insights, and updates about our clinical trials and advancements in the field of psychedelic research.

Sign up here to stay connected: https://www.sunstonetherapies.com/newsletter/

10/17/2025

CEO, Dr. Manish Agrawal, recently sat down with Dan Callahan, founder of HealingCancerJourneys.org.

Through caring for thousands of cancer patients, Dr. Agrawal witnessed how the deepest suffering—questions of meaning, grief, and love—often remains unaddressed in modern medicine. Psychedelics can help bring this essential dimension of healing to the forefront.

🎧 Listen to the full conversation: https://www.youtube.com/watch?v=nLnxllw6WcM

10/14/2025

Healing takes more than medicine. It takes understanding.

Sunstone is gathering perspectives on emotional health and well-being during serious illness or significant life changes.

Every response helps researchers learn how people are coping, finding balance, and seeking support.

Add your voice to the conversation.
Anonymous. Compassionate. Grounded in science.

Survey Link: https://chat.goodchats.co/gc/life-after-diagnosis

10/10/2025

Today, on , we acknowledge the profound need for compassionate mental health care.

At Sunstone Therapies, our mission is driven by a deep belief in whole-person healing. We know that suffering and trauma can quietly affect everything—from our relationships to our sense of meaning. That’s why we’re building a new standard of care rooted in love and rigor.

Healing is rarely a single moment; it’s an ongoing process of self-discovery, integration, and connection. Our commitment is to help every person navigate their journey with courage and resilience.

10/09/2025

We're thrilled to announce that our therapist, Jess M. Jones, LCSW-C, was selected for Psychedelic Alpha's inaugural issue of The Psychedelic Practitioner Newsletter in their "In Practice" series!

As a study therapist at Sunstone Therapies, Jess's insights are helping to shape the future of patient-centered care in this emerging field.

📑 Read the full issue on Psychedelic Alpha's website
https://psychedelicalpha.com/practitioner

10/01/2025

Sunstone is enrolling for the ELUMINA trial, a study researching an investigational treatment in patients with treatment resistant major depressive disorder (TRD). The investigational study medicine, called VLS-01 Buccal Film, is similar to DMT.

📧 clinical.specialists@sunstonetherapies.com to see if you or someone you care about may qualify

Learn more: https://www.sunstonetherapies.com/science/clinical-trials/a-study-to-assess-the-efficacy-safety-and-tolerability-of-vls-01-buccal-film-compared-to-placebo-in-patients-with-treatment-resistant-depression-trd/

09/30/2025

A core principle of our work is that therapeutic support for cancer patients must address the deepest questions of life. This guiding principle is the foundation of our new paper in Psychedelic Medicine, a collaboration with Memorial Sloan Kettering Cancer Center.

Our research outlines the MCP-PSIL model, which leverages Meaning-Centered Psychotherapy to guide patients through psilocybin treatment with greater purpose and clarity. This approach is a powerful tool that addresses questions of identity, legacy, and the meaning of life, which align with the intentions people often bring to psychedelic work.

📑 https://www.sunstonetherapies.com/research-paper-highlights-meaning-centered-psychotherapy-for-psilocybin-therapy-in-cancer-care/

09/23/2025

At Sunstone, we believe healing goes deeper than the surface.

In our very first clinical study, we saw that 80% of participants experienced a greater than 50% reduction in depressive symptoms—and half went into complete remission. The results were so meaningful, they were published in JAMA Oncology.

Building on that work, we’re now conducting the 2Dose Study, exploring psilocybin-assisted therapy in people with cancer of all stages to address two important questions:

▪️Is psilocybin more effective than an active placebo?
▪️Are two doses better than one?

Hear from our CEO and Principal Investigator, Dr. Manish Agrawal, as he discusses this study in more detail. https://www.sunstonetherapies.com/sunstones-2dose-study-advancing-psilocybin-assisted-therapy-in-cancer-care/

09/18/2025

Great news! We've launched a new module on our website to make searching our clinical trials database even easier.

You can now filter studies by compound and indication to quickly find the information you need. Looking for studies that are currently recruiting? You can filter by enrolling and upcoming studies, as well as review closed studies.

We're pleased to offer this improved resource to help you better navigate clinical research.

09/11/2025

Sunstone is enrolling for the APPROACH trial, a study researching an investigational treatment for depression, combined with psychological support, to learn how effective it might be at reducing symptoms of major depressive disorder (MDD). The investigational study medicine, called CYB003, is similar to psilocin (the active ingredient in Psilocybe mushrooms).

Contact us today to see if you or someone you care about may qualify: clinical.specialists@sunstonetherapies.com

To learn more about this study, click here:
https://www.sunstonetherapies.com/science/clinical-trials/a-phase-3-trial-to-assess-cyb003-psilocybin-analog-in-major-depressive-disorder-2/

09/09/2025

Sunstone is currently enrolling for the REKINDLE Study that explores a potential new approach for emotional distress linked to a life-changing illness.

To learn more about this study, click here:

Explore RE104 for Adjustment Disorder in Serious Illness and its potential benefits. Learn more about this exciting study.